학술논문
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S782-S783
Subject
Language
ISSN
0923-7534